GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » Other Operating Expense

Forty Seven (Forty Seven) Other Operating Expense : $-0.00 Mil (TTM As of Dec. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Forty Seven Other Operating Expense?

Forty Seven's Other Operating Expense for the three months ended in Dec. 2019 was $-0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2019 was $-0.00 Mil.

Forty Seven's quarterly Other Operating Expense increased from Jun. 2019 ($-0.00 Mil) to Sep. 2019 ($0.00 Mil) but then declined from Sep. 2019 ($0.00 Mil) to Dec. 2019 ($-0.00 Mil).

Forty Seven's annual Other Operating Expense stayed the same from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($0.00 Mil) but then declined from Dec. 2018 ($0.00 Mil) to Dec. 2019 ($-0.00 Mil).


Forty Seven Other Operating Expense Historical Data

The historical data trend for Forty Seven's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forty Seven Other Operating Expense Chart

Forty Seven Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Other Operating Expense
- - - -

Forty Seven Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Forty Seven Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forty Seven Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Forty Seven's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Forty Seven (Forty Seven) Business Description

Traded in Other Exchanges
N/A
Address
1490 O’Brien Drive, Suite A, Menlo Park, CA, USA, 94025
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Executives
Dennis Henner director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball director C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads officer: Chief Financial Officer 4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird director 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c. 10 percent owner C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154